| This is the talk page for discussing improvements to the Ranolazine article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Ranolazine.
|
Merlin / TIMI 36
editThe TIMI 36 trial is a large trial featuring ranolazine in individuals with NSTEMI. The results of the trial should be available by the end of March, 2007. Ksheka 17:20, 8 February 2007 (UTC)
about last sodim chennal effct on human
editnew renolazin has on long term report & only on animal they give resulst —Preceding unsigned comment added by 123.236.254.76 (talk) 14:39, 18 February 2009 (UTC)
Recent Edits
editDear All
My name is Mark and I work for Menarini, the European licence holder for ranolazine. Can I ask why most of the clinical information has been deleted? We thought it was quite useful.
Mark — Preceding unsigned comment added by 91.84.34.227 (talk) 12:59, 10 November 2014 (UTC)
- Thanks for talking! I am the editor who made the changes. This article did not follow the WP:MEDMOS guideline for how medical articles are written and structured, nor was it sourced according to our guideline for health-related articles, WP:MEDRS. I brought it in line with Wikipedia standards. Please do read both those links and let me know if you have any further questions. Jytdog (talk) 14:07, 10 November 2014 (UTC)
- Thank you for your reply. — Preceding unsigned comment added by 91.84.34.227 (talk) 14:36, 10 November 2014 (UTC)
- hey Mark, since you are here, do you know what happened with the ex-US/European rights? I was only able to find a source that SyntexRoche licensed US & european rights to CV Therapeutics, but nothing about asia etc. Do you know, and even better, do you know of any public source that describes that? Thanks Jytdog (talk) 14:42, 10 November 2014 (UTC)
- Thank you for your reply. — Preceding unsigned comment added by 91.84.34.227 (talk) 14:36, 10 November 2014 (UTC)
- The rights were bought by A Menarini for Europe and Asia and and by Gilead in the US — Preceding unsigned comment added by 91.84.34.227 (talk) 16:43, 10 November 2014 (UTC)
- i found the answer myself. It looks like Menarini have never bought anything related to ranolazine - the deals were not acquisitions but rather licenses. unless there is something i am missing. thanks though Jytdog (talk) 17:11, 10 November 2014 (UTC)
- Hi. Menarini effectvely bought the rights to market the medicine in Europe and Asia. By this, we took on the licence (or more correctly the Marketing Authorisation in Europe - not sure what the technical term is in Asiancountries. The patent is still held by the originator company. As you realise, companies buy and sell drugs to each other at 'different levels'. Sometimes the patent is sold on, sometimes just the rights to market it. — Preceding unsigned comment added by 91.84.34.227 (talk) 13:50, 11 November 2014 (UTC)
- There is a difference between acquisition and licensing. Many people here understand the difference and there is no reason to dumb it down. Jytdog (talk) 14:09, 11 November 2014 (UTC)